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Background: Despite potent antiretroviral therapy, HIV still causes brain damage. Better pen-
etration into the CNS and efﬁcient elimination of monocyte/macrophages reservoirs are two
main characteristics of an antiretroviral drug that could prevent brain damage. The aim of
our study was to assess efﬁcacy of three antiretroviral drug scores to predict brain atrophy
in  HIV-infected patients.
Methods: A cross sectional study consisting of 56 HIV-infected patients with controlled
viremia, who had no clinically evident neurocognitive impairment. All patients had MRI
of  the head. A typical T2 transversal slice was analyzed and ventricles–brain ratio (VBr) as
an  overall brain atrophy index was calculated. Three antiretroviral drug scores were used
and  correlated with VBr: 2008 and 2010 CNS penetration effectiveness scores (CPE2008 and
CPE2010) and the recently established monocyte efﬁcacy (ME) score. A p-value <0.05 was
considered signiﬁcant.
Results: CPE2010 was signiﬁcantly associated with VBr in both univariate (r = −0.285,
p  = 0.033) and multivariate (  ˇ = −0.299, p = 0.016) regression models, while CPE2008 was not
(r  = −0.141, p = 0.300 and  ˇ = −0.156, p = 0.214). ME was associated with VBr in multivariate
model only (r = −0.297, p = 0.111 and  ˇ = −0.406, p = 0.029). Age and reported duration of HIV
infection were also signiﬁcant predictors of overall brain atrophy in multivariate regression
models.
Conclusions: Although based on similar type of research, CPE2010 is a superior drug score
compared to CPE2008. ME is an efﬁcient drug score in determining brain damage. BothCPE2010 and ME scores should be taken into account in preventive strategies of brain
atrophy and neurocogniti
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Introduction
Different neuropathological and neuroradiological studies
have shown that HIV-infected patients have signiﬁcant
reduction of the brain parenchyma of both cortical1,2 and
subcortical brain regions.3,4 Despite effective HIV treatment,
brain tissue remains susceptible to the virus1 as there is
still detectable viral load in cerebrospinal ﬂuid (CSF),5 brain
volume loss6–8 and neurocognitive (NC) impairment.9,10 As
shown in euroSIDA study, antiretroviral therapy signiﬁcantly
reduced the incidence of NC disorders caused by HIV,11 but
its prevalence is still high (15–40%).12 Due to the blood–brain
and the blood–CSF barriers, drug entry into the CNS is limited,
which results in incomplete viral suppression in the CNS. That
might be the reason why CNS acts as a reservoir for viral
persistence and evolution of drug resistance, in which the
virus acquire unique properties.13,14 Different penetration lev-
els of antiretroviral drugs into the CNS have been quantiﬁed
by CNS-penetration effectiveness score (CPE), established by
Letendre et al.15 The score has 2008 (CPE2008) and 2010 (CPE2010)
versions.15,16 Higher CPE means not only a better penetration
efﬁcacy into the CNS, but also a decline of new CNS events
and even a decline in mortality rates.17 In contrast, a study by
McManus  et al.18 has not reached the same conclusion.
As viral reservoirs, circulating monocytes are consid-
ered to be responsible for chronic HIV infection in the
brain. Activated monocytes trafﬁc to the brain, where they
become macrophages and produce inﬂammatory molecules.
Increased inﬂammatory milieu results in damage of the brain
tissue and eventually leads to NC impairment.19–23 Autopsy
studies have shown increased number of macrophages in
brain despite antiretroviral treatment.24 Therefore, antiretro-
viral drugs that are effective in destroying viral reservoirs
(monocytes and brain macrophages) should slow down brain
atrophy and NC deterioration caused by HIV. Collecting in vitro
data about effectiveness of antiretroviral drugs against acti-
vated monocytes/macrophages, Shikuma et al. established
monocyte efﬁcacy (ME) score of drugs and proved its efﬁcacy
in predicting NC impairment.25
To our knowledge, there is only one study in which these
three drugs scores were compared and NC parameters were
used as outcome.25 There is no neuroimaging study in which
ME score was validated and compared with CPE scores in
assessing brain atrophy in HIV-infected patients.
The aim of our study was to compare recently established
ME score with two CPE scores in terms of efﬁcacy in predict-
ing brain atrophy in HIV-infected patients. We also wanted
to investigate other potential determinants of brain atrophy,
such as age, nadir and current CD4+ T-cell count and durations
of HIV infection and HAART.
Materials  and  methods
Study  design  and  subjectsThis cross-sectional study consisted of HIV-infected patients
receiving care at the HIV/AIDS Center, Infectious Diseases
Clinic, Clinical Center of Vojvodina in Novi Sad, Serbia. There
were 81 patients, who  had undergone MRI  of the brain, which 1 5;1  9(5):503–509
is around one-third of all registered patients. All MRIs were
performed at the Diagnostic Imaging Center, Oncology Insti-
tute in Sremska Kamenica, Serbia from July 2011 to July 2014.
Out of the 81 patients, 63 were on HAART and had plasma
HIV RNA < 50 copies/mL for at least three months. Exclusion
criteria were presence of focal brain changes on MRI, clinically
evident NC impairment, co-infection with hepatitis C virus,
and intravenous drug use. In a total of 56 patients who  met  all
the above criteria (Suppl. 1) the International HIV Dementia
Scale (IHDS) was applied as a neuropsychological screening
test, established by Sacktor et al.26 in which 0 is the worst and
12 is the best score. The study is a part of a larger project,
which has been approved by the local ethics committee and
informed consent was obtained from each patient.
Morphometry
For every included patient typical T2 transversal MRI  slices
were obtained in which lateral ventricles are most visible.
Ventricular–brain ratio (VBr) was calculated by measuring lat-
eral ventricles area and dividing by the brain area at the same
level. This is a marker of overall brain atrophy and has already
been used in studies on brain atrophy related to diseases
including HIV.27,28
Antiretroviral  drugs  and  drug  scoring  systems
All patients were on highly active antiretroviral therapy
(HAART) that consisted of two nucleoside reverse transcrip-
tase inhibitors (NRTI) plus a protease inhibitor (PI) and/or
non-nucleoside reverse transcriptase inhibitor (NNRTI). Three
antiretroviral drug-scoring systems were used: 2008 and 2010
(CPE2008 and CPE2010) CPE score versions,15,16 and ME  score.25
All scores for antiretroviral regimens were calculated as a
sum of the individual grades from the score. There are no
published data on ME score of lopinavir/ritonavir (lpv/r) and
darunavir. Therefore, for 26 (46.4%) patients, who  were on lpv/r
or darunavir, it was not possible to calculate ME values.
Statistical  analyses
Data were evaluated and statistically processed using the
software package IBM SPSS Statistics ver. 21. T-test for inde-
pendent samples was used to assess differences in means
of brain atrophy index between two groups. Pearson’s coef-
ﬁcient was used for estimating correlation between brain
atrophy index and parameters, such as age, nadir and current
CD4+ T-cell count, duration of HIV, duration of HAART, and
drug scores. Multivariate linear regression analyses were per-
formed for assessing predictors of brain damage. All tests were
two-tailed. A p < 0.05 was considered statistically signiﬁcant.
Results
Mean age of patients in the study was 41 years, 89% were
males. Demographic and virologic characteristics of the
patients are shown in Table 1.
Lamivudine was taken by 94.6%, abacavir by 67.9%,
lpv/r by 44.6%, efavirenz by 42.9%, zidovudine by 30.4%,
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aquinavir/ritonavir by 10.7%, didanosine by 5.4%, nevirapine
y 3.6%, and darunavir by 1.8% of patients (Fig. 1). Based on the
resence of efavirenz in the regimen the patients were cate-
orized into two groups. There were no signiﬁcant differences
n VBr (p = 0.926) and IHDS (p = 0.501) values between these two
roups.
Mean values, SD, medians, IQR, minimal and maximal
alues of CPE2008, CPE2010, and ME scores are shown in
able 2. ME signiﬁcantly correlated with CPE2010 (r = 0.546,
 = 0.002), while the association between ME and CPE2008
as not signiﬁcant (r = 0.097, p = 0.609). Correlation between
wo the CPE versions (CPE2008 and CPE2010) was highly sig-
iﬁcant (r = 0.644, p < 0.001).
A linear regression model was built including each of the
hree drug scoring systems. The independent variables age,
adir and current CD4+ T-cell count, duration of HIV status
nd HAART therapy were included in each of the three regres-
ion models. The dependent variable in all models was VBr,
 measure of brain atrophy. Results of these linear regression
Table 1 – Characteristics of patients. Data are shown as
mean value (SD) or percentage.
Total (n = 56)
Demographics
Age, years 41.1 (9.6)
Male gender 89%
Virology and therapy
Nadir CD4+ T-cell count, cells/mm3 186.0 (112.5)
Current CD4+ T-cell count, cells/mm3 472.5 (254.1)
HIV-positive status, months 69.9 (52.6)
Duration of therapy, months 39.4 (35.4)
Neuropsychological screening
IHDS, points 10.9 (1.0)
Brain morphometry
VBr, ×1000 84.2 (16.2)
IHDS, International HIV Dementia Scale; VBr, ventricles–brain ratio.use by study participants.
models are presented in Table 3. In univariate analyses age
(r = 0.283, p = 0.035) and CPE2010 (r = −0.285, p = 0.033) were
found to be signiﬁcantly associated with brain atrophy. How-
ever, in multivariate analyses, both CPE2010 and ME were
signiﬁcant predictors of brain atrophy (  ˇ = −0.299, p = 0.016 and
 ˇ = −0.406, p = 0.029, respectively). CPE2008 was neither sig-
niﬁcantly associated in univariate (r = −0.141, p = 0.300) nor in
multivariate (  ˇ = −0.156, p = 0.214) regression models. Age and
duration of HIV-positive status were parameters that were
signiﬁcantly associated with brain atrophy in all three mul-
tivariate models (Table 3).
Discussion
Numerous studies emphasized basal ganglia as the main
region in which pathological effects of HIV  take place in the
CNS.4,6 Other studies showed that numerous cortical parts of
the brain are damaged as well.29,30 Therefore, we  have used
VBr in our study, as an index of overall brain atrophy.
Our hypothesis was that the level of an antiretroviral drug
in the CNS affects all steps in the neuropathogenesis chain.
The ﬁrst step includes inﬂammatory changes and neuro-
logical injury. It can be diagnosed with CSF markers and
magnetic resonance spectroscopy. Atrophic changes occur
Table 2 – Mean, median and measures of dispersion for
three drug scores of patients in the study.
Mean SD Median IQR Range
CPE2008 2.16 0.45 2 2.0–2.5 1–3
CPE2010 8.18 0.81 8 8–9 6–10
ME 152.80 35.52 153 153–170 73–200
CPE2010, CNS-penetration effectiveness score (version 2010) of the
HAART regimen.
CPE2008, CNS-penetration effectiveness score (version 2008) of the
HAART regimen.
ME, monocyte efﬁcacy score of the HAART regimen.
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Table 3 – Linear regression models of three drug scoring systems with brain atrophy index (VBr) as a dependant variable.
Regression model Independent variables Univariate Multivariate
Correlation
coefﬁcient r
p Regression
coefﬁcient ˇ
p Model
signiﬁcance
CPE2010 Age 0.283 0.035 0.390 0.003 p = 0.001
Nadir CD4+ count −0.113 0.406
Current CD4+ count −0.112 0.413
Duration of HIV 0.235 0.082 0.291 0.022
Duration of HAART 0.238 0.078
CPE2010 −0.285 0.033 −0.299 0.016
CPE2008 Age 0.283 0.035 0.365 0.006 p = 0.008
Nadir CD4+ count −0.113 0.406
Current CD4+ count −0.112 0.413
Duration of HIV 0.235 0.082 0.322 0.015
Duration of HAART 0.238 0.078
CPE2008 −0.141 0.300 −0.156 0.214
ME Age 0.283 0.035 0.348 0.045 p = 0.022
Nadir CD4+ count −0.113 0.406
Current CD4+ count −0.112 0.413
Duration of HIV 0.235 0.082 0.377 0.043
Duration of HAART 0.238 0.078
ME −0.297 0.111 −0.406 0.029
CPE2010, CNS-penetration effectiveness score (version 2010) of the HAART regimen.
AARTCPE2008, CNS-penetration effectiveness score (version 2008) of the H
ME, monocyte efﬁcacy score of the HAART regimen.
in the second step, which can be evaluated with different
neuroimaging methods. Structural damage further results in
functional changes, the hallmark of the third step. These
functional changes are observed as NC impairment and can
be diagnosed using different neuropsychological tests. This
integral approach has been proved with correlations between
structural and functional variables in numerous studies,3,31–35
although there are also studies in which correlations were not
shown.2,6
One of the aims of our study was to compare two CPE
scoring systems. The original CPE2008 scoring system was
based on clinical, pharmacological and chemical reports on
antiretroviral drugs. In literature it was mostly indicated as
a predictor of decreasing viral load in CSF15,36; in neuropsy-
chological studies the results are controversial.37–40 Imaging
studies failed to prove CPE2008 as a predictor of brain
atrophy.4,7,8 Our results are in line with published reports as
we found no signiﬁcant association between CPE2008 and VBr.
Although such an outcome was expected due to similar
results previously reported, we  hypothesized that CPE2008
could be used to predict brain atrophy as it strongly corre-
lates with CPE2010. There are some possible reasons why the
association is not shown:
– Sum of score values range is too narrow to show small dif-
ferences.
– CPE scale classiﬁes drugs into only three categories, mask-
ing the differences among drugs in the same category.
On the contrary, a revised CPE was shown to be a good2010
predictor of brain atrophy in both univariate and multivariate
regression models. According to our results, it is expected that
HAART regimens consisting of drugs with higher CPE2010 score regimen.
have a protective effect on the brain tissue. The study by Cic-
carelli et al., using NC performance as the outcome of interest,
found results regarding CPE2008 and CPE2010 similar to our
study. In their study CPE2010 was emphasized as an improved
predicting tool and a step forward compared to CPE2008.41
There are very few neuroimaging studies that have
examined CPE2010. Ragin et al. conducted a neuroimaging
study that showed association between brain atrophy and
CPE2010.29 On the contrary, there are numerous studies in
which NC performance was used as an outcome. Some studies
have shown signiﬁcant positive association, whereas others
have not shown any association; furthermore, other studies
have found even worse NC performance in patients who  were
on higher CPE drug regimens.31,41–43 Possible reasons for such
discrepancy might be heterogonous cohorts regarding viro-
logical status and NC performance, HCV co-infection, and
intravenous drug use among examined patients. Therefore,
our cohort consisted only of neuroasymptomatic patients
with HIV RNA < 50 copies/mL for at least three months. In
order to reduce possible biases,44,45 we excluded HCV-HIV
co-infected patients and intravenous drug users. Thus, a rel-
atively homogenous sample was gathered representing the
majority of our HIV-infected patients. Further longitudinal
studies are needed to provide more  data about exact inﬂu-
ences of different variables on brain damage in these patients.
Possible neurotoxic effects of drugs with better penetra-
tion mentioned in several studies38,39,43 were not identiﬁed in
our study. Efavirenz is the most often emphasized drug for its
potential neurotoxicity.46 However, in our study the relation-
ship between the use of efavirenz and brain damage was not
found.
Reported duration of HIV infection was signiﬁcantly asso-
ciated with brain atrophy. Results suggest that chronic
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nfection of the CNS permanently damages brain tissue and
auses brain atrophy, which has been documented in the
iterature.4,30,34 Hidden behind blood–brain barrier, relatively
solated environment increases the magnitude of damage.
his ﬁnding suggests that patients should be always asked to
rovide, if possible, approximate date of infection with HIV, as
his information might be important to estimate the extent
f brain atrophy. The obvious problem of this parameter is
ts subjective nature. Often it is not possible to establish the
pproximate time of infection due to large number of part-
ers and rarity of testing. As life expectancy of HIV-infected
atients continuously increases, duration of HIV positive sta-
us also increases. According to our results, higher CPE2010
ight decrease effects of HIV duration in terms of brain atro-
hy.
Surprisingly, other HIV-related parameters, nadir and cur-
ent CD4+ T-cell count, were not associated with VBr in our
tudy. As for nadir CD4+ T-cell count, results suggest that brain
trophy is affected more  by the duration of immune compro-
ise than its “depth”. A failure to prove signiﬁcant association
etween brain atrophy and current CD4+ T-cell count could
e explained by individualized pattern of the immunological
ecovery in patients with undetectable viral load. Therefore
ts effect on the CNS is unpredictable. In literature, results in
egard to effects of nadir and current CD4+ T-cell count on
rain damage extent/NC impairment are controversial.1,6,29,47
Duration of HAART was signiﬁcantly associated with VBr
n univariate analyses, similar to duration of HIV. Duration of
AART and duration of HIV are highly correlated with each
ther. For this reason it was necessary to select one of these
wo  variables for multivariate analyses. As duration of HAART
epends on the duration of HIV, we  have included duration of
IV in multivariate analyses. A similar reasoning was used in
he study by Kuper et al.8
As it was already mentioned, this is the ﬁrst neuroimaging
tudy, to our knowledge, in which association between a neu-
oimaging parameter and ME  score is investigated. ME score
s based on the hypothesis that suppression of HIV in the CNS
ctually means elimination of monocyte/macrophage reser-
oirs. Our results showed that ME is negatively associated
ith brain damage, suggesting that drugs that are effective
n eliminating monocyte/macrophage reservoirs might pro-
ect brain tissue from injury. Similar results were shown in
he study by Shikuma et al., in which ME  score was associated
ith NC performance.25
Effective ME drug regimens provide a completely new
nsight in prevention and treatment of the neurocognitive dis-
rders caused by HIV. Elimination of reservoirs can start even
efore activated monocytes cross the blood–brain barrier and
ontinues as brain macrophages enter into the CNS. In that
ense, theoretically the ideal antiretroviral drug would be one
hat effectively destroys monocyte/macrophage reservoirs (in
he periphery and in the CNS) and penetrates well into the
NS. So, combining both CPE and ME  drug scores and integrat-
ng both qualities of a drug would be a step forward to a better
nderstanding of pathological effects of HIV in the CNS and
ffects of HAART onto counteracting them. For establishing
uch a scoring system, larger cohorts and further investiga-
ion on pharmacokinetics and pharmacology of the drugs are
eeded.5;1 9(5):503–509 507
In that sense, HAART regimens with high ME values could
be more  effective in clearing latent reservoirs not only in the
CNS, but also throughout the whole body, as systemic clearing
viral reservoirs would lead to eradication of the HIV.48 To prove
this, longitudinal studies are needed.
The main limitation of ME score is lack of known ME
values for darunavir, atazanavir, and most importantly for
lpv/r, although it is well known that this drug accumulates
in monocytes.49 Further in vitro analyses are needed to deter-
mine acute infection EC50 values of these drugs and calculate
their ME values.
Conclusions
Although the sample size might seem small and a follow-up
would be a logical next step, the expensive and sophisticated
imaging methods used in this study are not done routinely.
Previous similar neuroimaging studies were done on a sim-
ilar or even smaller sample. Although the marker used in
this study was used in other studies on brain atrophy, there
are now more  accurate techniques to deﬁne brain volumes.
Despite these limitations, our results suggest a few impor-
tant conclusions. Firstly, CPE2010 is a superior drug-scoring
system compared to CPE2008. Secondly, ME is an effective
drug-scoring system in determining brain damage. Thirdly,
both CPE2010 and ME scores should be taken into account
in preventing strategies of brain atrophy and NC impairment
in HIV-infected patients.
Controversial results in literature concerning drug-scoring
systems underscore the need for a new scoring system. One of
the possibilities is to build a mathematical model combining
CPE2010 and ME scores, in which both important qualities of
a drug (penetration in the CNS and elimination of reservoirs)
would be presented. This would require larger longitudinal
studies. The use of ME scoring system is limited due to miss-
ing values for some common HIV drugs, such as darunavir,
atazanavir, and lpv/r.
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